连环治疗, pembrolizumab 和 TACE 在中期HCC患者中显著改善了PFS,但严重副作用的发生率更高. Combination of lenvatinib, pembrolizumab and TACE significantly improved PFS in intermediate-stage HCC patients, but with higher severe side effects rate.
一项 3 期研究 LEAP-012 发现，lenvatinib 和 pembrolizumab 联合经动脉化疗栓塞术 （TACE） 显着改善了中期肝细胞癌 （HCC） 患者的无进展生存期 （PFS）。 A phase 3 study, LEAP-012, found that the combination of lenvatinib and pembrolizumab with transarterial chemoembolization (TACE) significantly improved progression-free survival (PFS) for patients with intermediate-stage hepatocellular carcinoma (HCC). 单独使用TACE的PFS中位数为14. 6个月,而仅使用TACE的PFS中位数为10个月. Median PFS was 14.6 months versus 10 months for TACE alone. 虽然综合结果显示出效果,但也导致严重副作用率较高,影响到71.3%的病人。 While the combination showed efficacy, it also resulted in higher rates of severe side effects, affecting 71.3% of patients.